Cite

HARVARD Citation

    Bohm, M. et al. (2020). Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary pharmacology & therapeutics. 52 (4), pp. 669-681. [Online]. 
  
Back to record